


Obr. 4. Vývoj neutralizačních protilátek proti SARS-CoV-2 (Ziemssen et al., 2022)



## LITERATÚRA

1. Berlit P. Leitlinien für Diagnostik und Therapie in der Neurologie der Kommission Leitlinien der Deutschen Gesellschaft für Neurologie in Zusammenarbeit mit der Deutschen Gesellschaft für Neurointensiv- und Notfallmedizin und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie publiziert bei. Available from: [www.awmf.org](http://www.awmf.org).
2. Cross AH, Delgado S, Habek M, et al. COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab. *Neurol Ther*. 2022;11(2):741-758.
3. El-Sayed A, Aleya L, Kamel M. Covid-19: a new emerging respiratory disease from the neurological perspective. *Environmental Sci Pollution Research*. 2021. <https://doi.org/10.1007/s11356-021-12969-9>.
4. European Centre for Disease Prevention and Control – Immune responses and immunity to SARS-CoV-2. Available from: <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses>.
5. Hauser SL, Bar Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. *N Engl J Med*. 2020;383:546-557.
6. Hauser SL, Cross H, Winthrop A, et al. Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis. *AAN*. 2022: P5.005.
7. Hauser SL, Cross H, Winthrop A, et al. Long-term effi-

cacy of ofatumumab in patients with relapsing multiple sclerosis. *AAN*. 2022: P5.005.


8. Keyhanian K, Umerton RP, Mohit B, Davoudi V, Hajjighasemi F, Ghasemi M. SARS-CoV-2 and nervous system: from pathogenesis to clinical manifestation. *J Neuroimmunol*. 2021;350:577436. <https://doi.org/10.1016/j.jneuroim.2020.577436>.
9. Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. *JAMA Neurology*. 2020;77(9). <https://doi.org/10.1001/jamaneuro.2020.2581>.
10. Maggi E, Canonica GW, Moretta L. Covid-19: Unanswered questions on immune response and pathogenesis. *Journal of Allergy and Clinical Immunology*. 2020;146(1):18-22. <https://doi.org/10.1016/j.jaci.2020.05.001>.
11. Möhn N, Konen FF, Pul R, et al. Experience in multiple sclerosis patients with covid-19 and disease-modifying therapies: a review of 873 published cases. *J Clin Med*. 2020;9:4067. doi:10.3390/jcm9124067.
12. Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. *JAMA Neurology*. 2021. <https://doi.org/10.1001/jamaneuro.2021.0688>.
13. Sormani MP, de Rossi N, Schiavetti I, et al. Disease-

zikozejšiu v súvislosti s infekciou COVID-19. Nové dáta zo štúdie ALITHIOS a KYRIOS priniesli priaznivé správy pre pacientov liečených ofatumumabom. Nezistilo sa vyššie riziko ťažšieho priebehu alebo vyššej úmrtnosti na COVID-19 v porovnaní s ostatnou populáciou a väčšina prípadov bola nezávažná. U všetkých očkovaných pacientov počas liečby ofatumumabom došlo po vakcinácii k vytvoreniu imunitnej odpovede a k infekcii došlo iba v malom počte osôb. Limitáciou týchto štúdií môžu byť prísne vstupné kritériá, ktoré nemusia odrážať stav reálnej populácie pacientov s RS. V štúdiu KYRIOS bol zahrnutý malý počet pacientov. Výraznejší náhľad do problematiky COVID-19 u pacientov s RS nám prinesú dáta z reálnej klinickej praxe zbierané vo veľkých registroch.

-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Annals of Neurology*. 2021;89(4). <https://doi.org/10.1002/ana.26028>.

14. Sospedra M. B cells in multiple sclerosis. *Current Opinion in Neurology*. 2018;31(3):256-262.
15. Stastna D, Menkyova I, Drahota J, et al. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. *Mult Scler Relat Disord*. 2021; 54:103104. doi:10.1016/j.msard.2021.103104.
16. SÚKL. Available from: [https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_cs.pdf).
17. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. *Journal of Immunology*. 2006;177(1):362-371.
18. Wang MY, Zhao R, Gao LJ F, et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development. *Front Cell Infect Microbiol*. 2020;10:587269. doi: 10.3389/fcimb.2020.587269.
19. Ziemssen T, Bopp T, Eittle B, et al. Kyrios clinical trial: Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab. *AAN*. 2022: P1.288.

## VĚRNÝM ČTENÁŘŮM



ZAZNĚLO NA  
10. konferenci  
Neurologie  
pro praxi v Plzni  
25.–26. 1. 2023

ZAZNĚLO NA

10. KONFERENCI NEUROLOGIE PRO PRAXI V PLZNI

25.–26. 1. 2023

Parkhotel Congress Center Plzeň